Citius Pharmaceuticals is trading 10.2% up today at $0.55, rebounding from recent weakness in the small-cap biotech space and previous dilution concerns.
- The upward move comes without fresh company-specific headlines, suggesting a technical recovery and positive sentiment spillover.
- Broader healthcare stocks are showing strength following robust Q2 earnings from sector leaders, providing a tailwind for the industry.
- The gains occur even as major indices trade lower ahead of the FOMC statement and amid heightened geopolitical tensions.